Core Insights - CDT Equity Inc. has completed initial signature mapping of its asset portfolio against Sarborg Limited's rare disease database, identifying multiple high-potential opportunities across various rare and underserved indications [1][2] Group 1: Asset Evaluation - The analysis utilized Sarborg's AI Signature Agent platform to evaluate CDT's portfolio, including its solid-form patent portfolio and licensed AstraZeneca compounds AZD1656 and AZD5658, against approximately 1,700 rare disease signatures [2] - The evaluation resulted in several statistically significant matches across therapeutic areas such as immunology, oncology, infectious disease, pediatric, and ophthalmology, indicating potential applications in orphan diseases [2] Group 2: Regulatory and Commercial Incentives - The findings are significant due to increasing regulatory and commercial incentives for rare disease development, which may include expedited regulatory pathways, smaller clinical trial designs, and enhanced market exclusivity, potentially reducing development timelines and capital requirements [3] Group 3: Strategic Advancement - CDT plans to advance these opportunities through focused, small-scale preclinical validation studies, including targeted in vivo work, to support the underlying signature data [4] - The resulting datasets are expected to form comprehensive packages for early-stage out-licensing discussions with potential partners [4] Group 4: Company Strategy - CDT's strategy focuses on identifying high-value opportunities through rapid, data-driven analysis and partnering these assets early with pharmaceutical companies or specialist investors [5] - The combination of Sarborg's signature intelligence platform and CDT's growing intellectual property portfolio offers a differentiated approach to identifying and monetizing therapeutic opportunities, particularly in high unmet medical need areas [5] Group 5: Market Potential - Certain identified opportunities are within oncology settings with limited or no currently marketed therapies, reinforcing the potential to address underserved patient populations while creating attractive partnership propositions [6]

Core Viewpoint - CDT Equity Inc. is advancing multiple initiatives aimed at enhancing shareholder value and expanding its strategic footprint through the development of its pharmaceutical asset portfolio and strategic acquisitions [1][2][3]. Group 1: Pharmaceutical Asset Development - The company is actively developing its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, and licensed clinical assets AZD1656, AZD5658, and AZD5904 under an agreement with AstraZeneca [2]. - CDT is engaged in ongoing evaluation and out-licensing discussions to maximize the commercial and strategic potential of its assets, believing that this diversified asset base provides several avenues for value realization [2]. Group 2: Strategic Acquisition - CDT has completed a strategic acquisition of a 20% equity stake in Sarborg for an initial consideration of $115 million, which allows shareholders to participate in a growing AI signature intelligence business that extends beyond pharmaceuticals [3]. - The acquisition was financed through the issuance of common stock and pre-funded warrants, which strengthens the company's balance sheet and enhances its overall asset position [3]. Group 3: Financial Position and Growth Strategy - The company believes it is well-positioned to evaluate transformative opportunities that could materially impact its balance sheet and market capitalization, continuing to assess strategic transactions, partnerships, and corporate initiatives [4]. - CDT is focused on pursuing transformational opportunities that enhance shareholder value through its investment in Sarborg, ongoing pharmaceutical portfolio development, and disciplined evaluation of strategic transactions [5]. Group 4: Commitment to Shareholder Value - CDT is committed to creating shareholder value through licensing, strategic mergers and acquisitions, and positioning itself as a platform for transformative innovation [7].

Core Insights - CDT Equity Inc. has identified a new biological target and therapeutic indication for its lead programme AZD1656, supported by positive pre-clinical trial data, affirming its AI-led drug repurposing strategy [1][3][4] - The company, in collaboration with Sarborg, utilized AI-powered disease mapping to analyze AZD1656 against a database of over 800 disease signatures, uncovering several new therapeutic indications [2][4] - The initial pre-clinical study results have validated the algorithmic findings, leading to plans for further studies to explore the commercial potential of the new biological target [3][4] Company Strategy - CDT has transitioned to a lean, disease-agnostic operating model informed by data-driven insights, successfully identifying novel indications for AZD1656 [4] - The company aims to progress AZD1656 towards a commercial out-licensing opportunity based on the positive outcomes of its research [4] Research and Development - Several pre-clinical studies have been initiated to explore the potential of AZD1656 in previously untapped therapeutic areas, leveraging a robust patent portfolio [2][3]

Core Insights - Conduit Pharmaceuticals has filed four new patent applications for its key assets AZD1656 and AZD5658, marking the first patent filings for AZD5658, which significantly expands the company's intellectual property portfolio [1][6] - The new patents are based on combinations of Conduit's lead assets with existing therapies, identified through AI-led analysis in collaboration with Sarborg Limited, enhancing the company's ability to generate novel, data-driven intellectual property [2][6] - The Chief Scientific Officer of Conduit Pharmaceuticals emphasized that these filings validate the progress made through the partnership with Sarborg, uncovering therapeutic combinations with substantial commercial potential [3] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [4] - The company utilizes a platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party licensing deals after successful clinical trials [4] - The leadership team includes experienced executives such as Dr. Andrew Regan and Dr. Freda Lewis-Hall, indicating a strong foundation for the company's innovative approach [4]

Core Insights - Conduit Pharmaceuticals has entered a joint development agreement with Manoira Corporation to evaluate its glucokinase activators AZD1656 and AZD5658 for veterinary applications, particularly in animal osteoarthritis [1][2][3] - The collaboration aims to generate preclinical data that will inform Conduit's human clinical programs while retaining full ownership of all related intellectual property [3][5][6] - This partnership opens new revenue streams in the growing $15 billion animal health market, projected to grow at a CAGR of 6.5% through 2027 [7][6] Company Strategy - The agreement highlights Conduit's commitment to innovative collaborations that maximize resource efficiency and pipeline potential [4] - By leveraging Manoira's expertise, Conduit aims to accelerate the development of AZD1656 and explore cross-species value through targeted programs [5][6] - The partnership is designed to enhance Conduit's competitive edge in glucokinase activator therapies and create a dual-track value proposition for shareholders [3][7] Financial Aspects - Manoira will fund all development activities, while Conduit will issue an upfront consideration of $500,000 through the issuance of 154,799 shares of common stock [8] - The collaboration is expected to reduce development timelines and costs for human clinical trials, enhancing the probability of success for AZD1656 in human indications [7][6] - The joint development agreement allows Conduit to retain exclusive rights and ownership of all new intellectual property related to AZD1656 and AZD5658 for human applications [5][4]

Core Insights - Conduit Pharmaceuticals has secured a composition of matter patent for its lead asset, AZD1656, from the Korean Intellectual Property Office, enhancing its global intellectual property position and facilitating clinical development and strategic partnerships [1][2] - The patent approval follows similar grants in the U.S., Japan, and Australia, indicating a robust international patent strategy that supports Conduit's growth in the Asia-Pacific pharmaceutical market [1][2] - The company aims to leverage its innovative approach to compound development, utilizing artificial intelligence and cybernetics, to create long-term value through global partnerships and licensing deals [2] Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on developing Phase 2-ready assets through an integrated platform-driven approach [2] - The leadership team, including Dr. Andrew Regan and Dr. Freda Lewis-Hall, emphasizes a departure from traditional pharmaceutical business models by seeking exits through third-party licensing after successful clinical trials [2]

Core Viewpoint - Conduit Pharmaceuticals Inc. has authorized a share repurchase program to buy back up to $1,000,000 of its common stock, believing the current market price does not reflect its underlying value [1][4]. Share Repurchase Program - The program allows Conduit to repurchase shares through open market transactions or other methods, adhering to SEC Rule 10b-18, with purchases executed by The Benchmark Company [2]. - There is no obligation for the company to acquire a specific amount of stock, and the program has no fixed expiration date, allowing for adjustments or termination at any time [3]. Company Overview - Conduit is a clinical-stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets [4]. - The company employs a platform-driven approach powered by artificial intelligence and cybernetics, aiming for exits through third-party license deals after successful clinical trials [4]. - The leadership team includes experienced pharmaceutical executives, indicating a strong foundation for the company's innovative approach [4].

Core Insights - Conduit Pharmaceuticals has expanded its partnership with Sarborg to utilize advanced machine learning for analyzing clinical data from AstraZeneca-acquired assets, aiming to optimize development pathways and uncover new insights [1][2] Group 1: Partnership Details - The new agreement allows Sarborg to apply its proprietary machine learning algorithms to analyze Conduit's clinical and safety data, focusing on identifying missed insights and potential drug repurposing opportunities [2] - The collaboration includes a non-exclusive, non-transferable license for Conduit to access Sarborg's advanced algorithmic platform for six months, building on an existing Services Agreement [3] Group 2: Strategic Goals - The partnership aims to re-evaluate historical clinical trial data to identify specific patient subgroups that may have shown therapeutic benefits, which could refine Conduit's future clinical development strategy [2] - Dr. David Tapolczay, CEO of Conduit Pharmaceuticals, emphasized the commitment to leveraging data science to maximize the potential of their pipeline, particularly for key assets like AZD1656 [4] Group 3: Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company focused on an efficient model for compound development, acquiring and funding Phase 2-ready assets while utilizing AI and cybernetics [4] - The company aims for exits through third-party license deals following successful clinical trials, representing a departure from traditional pharma/biotech business models [4]

Group 1: Company Overview - Conduit Pharmaceuticals has secured a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders such as Lupus and ANCA Vasculitis, positioning the company for clinical development and strategic partnerships [1][2] - The company is focused on developing Phase 2-ready assets and employs an integrated platform-driven approach powered by artificial intelligence (AI) and cybernetics, aiming for exit through third-party license deals following successful clinical trials [4] Group 2: Market Potential - The U.S. autoimmune disease market is projected to reach $150 billion by 2030, with Lupus affecting approximately 1.5 million Americans and ANCA Vasculitis impacting 200,000 patients annually, indicating a growing demand for innovative treatments [2] - Conduit's patent protection, which provides up to 20 years of exclusivity in the U.S., reinforces its competitive positioning and opens opportunities for commercial and strategic licensing partnerships [2][3] Group 3: Intellectual Property - Composition of matter patents are considered the gold standard in pharmaceutical intellectual property, offering strong market exclusivity and protection against generic competition [3] - The newly granted patent, along with existing approvals in Japan and Australia, positions Conduit favorably in three major pharmaceutical markets, with pending applications in Europe and other regions expected to expand its footprint [2]

As filed with the Securities and Exchange Commission on September 4, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 (I.R.S. Employer Identification Number) 4995 Murphy Canyon Road, Suite 300 San Diego, CA 92134 (760) 471-8536 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) David Tapolczay Chief Executive Officer Conduit Pha ...